Biodesix Closes Series D Financing - July 2011
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
254 Results
Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.
Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).
A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.
Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.
The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.
Biodesix, Inc., today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado.
Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).